Showing 7921-7930 of 9448 results for "".
DermwireTV: Deucravacitinib Maintains Efficacy in PsO at 3 Years
https://practicaldermatology.com/programs/practical-dermatology/dermwiretv-deucravacitinib-maintains-efficacy-in-pso-at-3-years/37249/In this episode of DermwireTV, deucravacitinib maintains efficacy for plaque psoriasis through 3 years in a new analysis; GLP-1 medications may be fueling a rise in aesthetic procedures, according to new research; and Drs. Tina Bhutani and Lisa Swanson weigh in on transitioning from academia to privProcedural Management for HS
https://practicaldermatology.com/programs/practical-dermatology/procedural-management-for-hs/35891/Vivian Shi, MD, talks about procedural management for hidradenitis suppurativa and how to incorporate those procedures with medical management of the condition at Music City SCALE 2025.Rosacea Treatment Options and Strategies
https://practicaldermatology.com/programs/practical-dermatology/rosacea-treatment-options-and-strategies/35893/Joel L. Cohen, MD, FAAD, and Hilary Baldwin, MD, talk at Music City SCALE 2025 about the latest treatment options for rosacea and strategies for getting patient buy-in.Fractional Lasers for NMSC and More
https://practicaldermatology.com/conferences/scale-2025/fractional-lasers-for-nmsc-and-more/35876/Joel L. Cohen, MD, FAAD, and Matthew M. Avram, MD, talk about research involving fractional lasers, including as part of combination treatments for nonmelanoma skin cancer, at Music City SCALE 2025.Nail Disease and JAK Inhibitor Safety
https://practicaldermatology.com/programs/practical-dermatology/nail-disease-and-jak-inhibitor-safety/35897/Brad Glick, DO, talks about the basics of nail anatomy, physiology, disease presentation, and treatments, as well as the safety of JAK inhibitors, at Music City SCALE 2025.Novel PsO Drug Could Be 'Closest Perception of a Cure,' Dr. Strober Says at Maui Derm
https://practicaldermatology.com/programs/practical-dermatology/novel-pso-drug-could-be-closest-perception-of-a-cure-dr-strober-says-at-maui-derm/32922/A novel monoclonal antibody targeting IL-23 for the treatment of psoriasis offers an extended half-life that will be a key differentiator for patients, according to Bruce Strober, MD, PhD.Dr. Eichenfield Urges Caution for Steroid-Phobia at Maui Derm
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/dr-eichenfield-urges-caution-for-steroid-phobia-at-maui-derm/32919/In addition to the various clinical skin conditions that pediatric patients present with, dermatologists now must understand how to deal with steroid-phobia, according to Lawrence Eichenfield, MD.Various Skin Cancer Therapies Covered at Maui Derm
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/various-skin-cancer-therapies-covered-at-maui-derm/32915/With a theme of understanding the various options available for treatment of skin cancers and selecting the correct ones for each case, George Martin, MD, Ted Rosen, MD, and Emily Ruiz, MD, MPH, presented “Cutaneous Oncology Update 2025” at the Maui Derm Hawaii 2025 meeting in Maui, Hawaii.Canadian Perspective: Drs. Bhatia, Sapijaszko, and Kaufmann
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/canadian-perspective-drs-bhatia-sapijaszko-and-kaufmann/32695/Neal Bhatia, MD, speaks with Canadian Dermatology Association vice president Mariusz Sapijaszko, MD, FAACS, and former American Academy of Dermatology president Mark Kaufmann, MD, about different perspectives on advocacy in dermatology, including the use of patient stories.Urticaria: Dr. Hawkes
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/urticaria-dr-hawkes/32690/Jason Hawkes, MD, talks about how to manage and approach chronic spontaneous urticaria patients, as well as novel therapeutic options, all of which he covered in "Urticaria Update 2025" at Maui Derm 2025.